| 1 | Management of cancer patients during COVID-19 pandemic at developing countries显示文摘Cancer patient care requires a multi-disciplinary approach and multiple medical and ethical considerations.Clinical care during a pandemic health crisis requires prioritising the use of resources for patients with a greater chance of survival,especially in developing countries.The coronavirus disease 2019 crisis has generated new challenges given that cancer patients are normally not prioritised for admission in critical care units.Nevertheless,the development of new cancer drugs and novel adjuvant/neoadjuvant protocols has dramatically improved the prognosis of cancer patients,resulting in a more complex decision-making when prioritising intensive care in pandemic times.In this context,it is essential to establish an effective and transparent communication between the oncology team,critical care,and emergency units to make the best decisions,considering the principles of justice and charity.Concurrently,cancer treatment protocols must be adapted to prioritise according to oncologic response and prognosis.Communication technologies are powerful tools to optimise cancer care during pandemics,and we must adapt quickly to this new scenario of clinical care and teaching.In this new challenging pandemic scenario,multi-disciplinary work and effective communication between clinics,technology,science,and ethics is the key to optimising clinical care of cancer patients. | Jaime González-Montero Guillermo Valenzuela Mónica Ahumada Olga Barajas Luis Villanueva | 2020 | World Journal of Clinical Cases2020，8，16： | 0 |
| 2 | Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study显示文摘BACKGROUND Colorectal cancer is a complex disease with high mortality rates.Over time,the treatment of metastatic colorectal cancer(mCRC)has gradually improved due to the development of modern chemotherapy and targeted therapy regimens.However,due to the inherent heterogeneity of this condition,identifying reliable predictive biomarkers for targeted therapies remains challenging.A recent promising classification system—the consensus molecular subtype(CMS)system—offers the potential to categorize mCRC patients based on their unique biological and molecular characteristics.Four distinct CMS categories have been defined:immune(CMS1),canonical(CMS2),metabolic(CMS3),and mesenchymal(CMS4).Nevertheless,there is currently no standardized protocol for accurately classifying patients into CMS categories.To address this challenge,reverse transcription polymerase chain reaction(RT-qPCR)and next-generation genomic sequencing(NGS)techniques may hold promise for precisely classifying mCRC patients into their CMSs.AIM To investigate if mCRC patients can be classified into CMS categories using a standardized molecular biology workflow.METHODS This observational study was conducted at the University of Chile Clinical Hospital and included patients with unresectable mCRC who were undergoing systemic treatment with chemotherapy and/or targeted therapy.Molecular biology techniques were employed to analyse primary tumour samples from these patients.RT-qPCR was utilized to assess the expression of genes associated with fibrosis(TGF-βandβ-catenin)and cell growth pathways(c-MYC).NGS using a 25-gene panel(TumorSec)was performed to identify specific genomic mutations.The patients were then classified into one of the four CMS categories according to the clinical consensus of a Tumour Board.Informed consent was obtained from all the patients prior to their participation in this study.All techniques were conducted at University of Chile.RESULTS Twenty-six patients were studied with the techniques and then evaluated by the Tumour Board to determine the specific CMS.Among them,23%(n=6),19%(n=5),31%(n=8),and 19%(n=5)were classified as CMS1,CMS2,CMS3,and CMS4,respectively.Additionally,8%of patients(n=2)could not be classified into any of the four CMS categories.The median overall survival of the total sample was 28 mo,and for CMS1,CMS2,CMS3 and CMS4 it was 11,20,30 and 45 mo respectively,with no statistically significant differences between groups.CONCLUSION A molecular biology workflow and clinical consensus analysis can be used to accurately classify mCRC patients.This classification process,which divides patients into the four CMS categories,holds significant potential for improving research strategies and targeted therapies tailored to the specific characteristics of mCRC. | Jaime González-Montero Mauricio Burotto Guillermo Valenzuela Debora Mateluna Florencia Buen-Abad Jessica Toro Olga Barajas Katherine Marcelain | 2023 | World Journal of Clinical Oncology2023，14，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员